Methods, systems, and apparatus for monitoring and controlling electronic devices using wired and wireless protocols are disclosed. The systems and apparatus may monitor their environment for signals from electronic devices. The systems and apparatus may take and disambiguate the signals that are received from the devices in their environment to identify the devices and associate control signals with the devices. The systems and apparatus may use communication means to send control signals to the identified electronic devices. Multiple apparatuses or systems may be connected together into networks, including mesh networks, to make for a more robust architecture.

The disclosure is directed to compounds of the formula (I): ##STR00001##
and uses of such compounds to treat neurodegenerative diseases and cancers.

The disclosure is directed to compounds of the formula (I): ##STR00001##
and uses of such compounds to treat neurodegenerative diseases and cancers.

Described are methods of prepraing reduced 3,7-diamino-10H-phenothiazine (DAPTZ) compounds of formula:

##STR00001##

wherein: R.sup.1 and R.sup.9 are independently selected from: —H; C.sub.1-4alkyl; C.sub.2-4alkenyl; and halogenated C.sub.1-4alkyl; each of R.sup.3NA and R.sup.3NB is independently selected from: —H; C.sub.1-4alkyl; C.sub.2-4alkenyl; and halogenated C.sub.1-4alkyl; each of R.sup.7NA and R.sup.7NB is independently selected from: —H; C.sub.1-4alkyl; C.sub.2-4alkenyl; and halogenated C.sub.1-4alkyl; each of HX.sup.1 and HX.sup.2 is independently a protic acid; and pharmaceutically acceptable salts, solvates, and hydrates thereof. These methods are particularly usefull for producing stable reduced forms, and with high purity. The stability and purity are especially relevant for pharmaceutical compositions for the treatment of disease. The compounds are useful for treatment of e.g. tauopathies, such as Alzheimer's disease, and also as prodrugs for the corresponding oxidized thioninium drugs.

Described are methods of prepraing reduced 3,7-diamino-10H-phenothiazine (DAPTZ) compounds of formula:

##STR00001##

wherein: R.sup.1 and R.sup.9 are independently selected from: —H; C.sub.1-4alkyl; C.sub.2-4alkenyl; and halogenated C.sub.1-4alkyl; each of R.sup.3NA and R.sup.3NB is independently selected from: —H; C.sub.1-4alkyl; C.sub.2-4alkenyl; and halogenated C.sub.1-4alkyl; each of R.sup.7NA and R.sup.7NB is independently selected from: —H; C.sub.1-4alkyl; C.sub.2-4alkenyl; and halogenated C.sub.1-4alkyl; each of HX.sup.1 and HX.sup.2 is independently a protic acid; and pharmaceutically acceptable salts, solvates, and hydrates thereof. These methods are particularly usefull for producing stable reduced forms, and with high purity. The stability and purity are especially relevant for pharmaceutical compositions for the treatment of disease. The compounds are useful for treatment of e.g. tauopathies, such as Alzheimer's disease, and also as prodrugs for the corresponding oxidized thioninium drugs.

An object of the present invention is to provide an organic electroluminescent element containing an organic layer interposed between an anode and a cathode, the organic layer containing at least one light emitting layer, wherein the at least one light emitting layer contains a π-conjugated compound having an electron donor portion and an electron acceptor portion in the molecule; the π-conjugated compound has a direction vector from an atom having a HOMO orbital in the electron donor portion to an electron cloud of the HOMO orbital, and a direction vector from an atom having a LUMO orbital in the electron acceptor portion to an electron cloud of the LUMO orbital, and the two direction vectors form an angle θ in the range of 90 to 180 degrees; and the π-conjugated compound has a plurality of the electron donor portions or a plurality of the electron acceptor portions.

An object of the present invention is to provide an organic electroluminescent element containing an organic layer interposed between an anode and a cathode, the organic layer containing at least one light emitting layer, wherein the at least one light emitting layer contains a π-conjugated compound having an electron donor portion and an electron acceptor portion in the molecule; the π-conjugated compound has a direction vector from an atom having a HOMO orbital in the electron donor portion to an electron cloud of the HOMO orbital, and a direction vector from an atom having a LUMO orbital in the electron acceptor portion to an electron cloud of the LUMO orbital, and the two direction vectors form an angle θ in the range of 90 to 180 degrees; and the π-conjugated compound has a plurality of the electron donor portions or a plurality of the electron acceptor portions.

It is related to compounds used as autophagy modulators and a method for preparing and using the same, specifically providing a compound of general formula (I), or pharmaceutically acceptable salts thereof, which is a type of autophagy modulators, particularly mammalian ATG8 homologues modulators. ##STR00001##

A rechargeable lithium-ion cell has a cell capacity and includes a positive electrode having a recharged potential and a negative electrode. The rechargeable lithium-ion cell also includes a charge-carrying electrolyte. The charge-carrying electrolyte includes a charge-carrying medium and a lithium salt. The rechargeable lithium-ion cell also includes a redox shuttle having the following structure Formula (I). ##STR00001##

A rechargeable lithium-ion cell has a cell capacity and includes a positive electrode having a recharged potential and a negative electrode. The rechargeable lithium-ion cell also includes a charge-carrying electrolyte. The charge-carrying electrolyte includes a charge-carrying medium and a lithium salt. The rechargeable lithium-ion cell also includes a redox shuttle having the following structure Formula (I). ##STR00001##